Compare Stocks: BWAY, ESTA, ATRC, and NVCR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$44.30 +1.9%	$33.91	$25.36 ▼ $44.48	$2.21B	1.2	904,317 shs	340,910 shs
BWAY Brainsway	$16.32 -0.9%	$15.18	$6.26 ▼ $17.40	$660.96M	1.24	173,039 shs	120,963 shs
ESTA Establishment Labs	$79.47 +5.1%	$86.79	$36.53 ▼ $97.59	$2.25B	1.07	574,767 shs	496,985 shs
NVCR NovoCure	$16.95 -2.5%	$16.36	$9.82 ▼ $21.45	$2.02B	0.97	1.73 million shs	681,217 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	-0.16%	+10.13%	+26.72%	+54.66%	+18.50%
BWAY Brainsway	-0.78%	+5.24%	+13.98%	+9.58%	+159.37%
ESTA Establishment Labs	+0.01%	-4.38%	-12.70%	+14.95%	+97.16%
NVCR NovoCure	-1.19%	+10.77%	+11.77%	-1.14%	+49.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$44.30 +1.9%	$33.91	$25.36 ▼ $44.48	$2.21B	1.2	904,317 shs	340,910 shs
BWAY Brainsway	$16.32 -0.9%	$15.18	$6.26 ▼ $17.40	$660.96M	1.24	173,039 shs	120,963 shs
ESTA Establishment Labs	$79.47 +5.1%	$86.79	$36.53 ▼ $97.59	$2.25B	1.07	574,767 shs	496,985 shs
NVCR NovoCure	$16.95 -2.5%	$16.36	$9.82 ▼ $21.45	$2.02B	0.97	1.73 million shs	681,217 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	-0.16%	+10.13%	+26.72%	+54.66%	+18.50%
BWAY Brainsway	-0.78%	+5.24%	+13.98%	+9.58%	+159.37%
ESTA Establishment Labs	+0.01%	-4.38%	-12.70%	+14.95%	+97.16%
NVCR NovoCure	-1.19%	+10.77%	+11.77%	-1.14%	+49.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRC AtriCure	2.82	Moderate Buy	$48.50	9.48% Upside
BWAY Brainsway	2.86	Moderate Buy	$16.95	3.86% Upside
ESTA Establishment Labs	2.78	Moderate Buy	$100.25	26.15% Upside
NVCR NovoCure	2.14	Hold	$21.20	25.07% Upside

Current Analyst Ratings Breakdown

Latest BWAY, ESTA, ATRC, and NVCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	ESTA Establishment Labs	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$92.00
8/13/2026	BWAY Brainsway	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $18.80
8/12/2026	BWAY Brainsway	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00
8/11/2026	BWAY Brainsway	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2026	ESTA Establishment Labs	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$84.00 ➝ $95.00
8/6/2026	ESTA Establishment Labs	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$105.00
8/6/2026	ESTA Establishment Labs	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$96.00 ➝ $103.00
8/6/2026	ESTA Establishment Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$86.00 ➝ $95.00
8/3/2026	ESTA Establishment Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $117.00
7/28/2026	ATRC AtriCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D+)
7/28/2026	ATRC AtriCure	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$55.00 ➝ $50.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRC AtriCure	$534.53M	4.22	$0.32 per share	138.95	$10.15 per share	4.36
BWAY Brainsway	$60.70M	10.79	$0.23 per share	70.35	$1.97 per share	8.28
ESTA Establishment Labs	$211.08M	11.22	N/A	N/A	$0.73 per share	108.86
NVCR NovoCure	$655.35M	3.01	N/A	N/A	$2.90 per share	5.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRC AtriCure	-$11.45M	$0.21	210.96	98.44	N/A	1.85%	2.34%	1.77%	N/A
BWAY Brainsway	$7.57M	$0.44	37.09	30.22	N/A	15.65%	12.74%	8.17%	N/A
ESTA Establishment Labs	-$51.06M	-$1.31	N/A	N/A	N/A	-15.82%	-196.69%	-10.73%	N/A
NVCR NovoCure	-$136.23M	-$1.30	N/A	N/A	N/A	-21.25%	-44.00%	-15.85%	10/29/2026 (Estimated)

Latest BWAY, ESTA, ATRC, and NVCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BWAY Brainsway	$0.10	$0.07	-$0.03	$0.07	$16.54 million	$17.11 million
8/6/2026	Q2 2026	ESTA Establishment Labs	-$0.3368	-$0.39	-$0.0532	-$0.39	$65.79 million	$67.54 million
7/23/2026	Q2 2026	ATRC AtriCure	-$0.0017	$0.18	+$0.1817	$0.18	$151.80 million	$153.60 million
7/23/2026	Q2 2026	NVCR NovoCure	-$0.3315	-$0.13	+$0.2015	-$0.13	$172.44 million	$183.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
BWAY Brainsway	N/A	N/A	N/A	N/A	N/A
ESTA Establishment Labs	N/A	N/A	N/A	N/A	N/A
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRC AtriCure	0.14	4.22	3.19
BWAY Brainsway	N/A	3.59	3.04
ESTA Establishment Labs	12.11	3.84	1.91
NVCR NovoCure	0.58	2.89	2.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRC AtriCure	99.11%
BWAY Brainsway	30.11%
ESTA Establishment Labs	72.91%
NVCR NovoCure	84.61%

Insider Ownership

Company	Insider Ownership
ATRC AtriCure	4.00%
BWAY Brainsway	19.00%
ESTA Establishment Labs	9.99%
NVCR NovoCure	6.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRC AtriCure	1,300	50.87 million	48.83 million	Optionable
BWAY Brainsway	120	40.13 million	32.51 million	Not Optionable
ESTA Establishment Labs	1,004	29.80 million	26.83 million	Optionable
NVCR NovoCure	1,605	116.45 million	108.82 million	Optionable

BWAY, ESTA, ATRC, and NVCR Headlines

Recent News About These Companies

Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet

August 12 at 10:56 AM | zacks.com

Sei Investments Co. Buys 89,839 Shares of NovoCure Limited $NVCR

August 12 at 4:23 AM | marketbeat.com

First Trust Advisors LP Invests $1.03 Million in NovoCure Limited $NVCR

August 11 at 3:27 AM | marketbeat.com

Dimensional Fund Advisors LP Buys 207,913 Shares of NovoCure Limited $NVCR

August 10, 2026 | marketbeat.com

NovoCure (NASDAQ:NVCR) Rating Increased to Buy at Wall Street Zen

August 8, 2026 | marketbeat.com

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

August 7, 2026 | zacks.com

NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Hold" from Brokerages

August 3, 2026 | marketbeat.com

Quantinno Capital Management LP Has $27.11 Million Stock Position in NovoCure Limited $NVCR

August 1, 2026 | marketbeat.com

NovoCure Limited $NVCR Shares Bought by Renaissance Technologies LLC

July 31, 2026 | marketbeat.com

Healthcare of Ontario Pension Plan Trust Fund Sells 201,000 Shares of NovoCure Limited $NVCR

July 29, 2026 | marketbeat.com

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?

July 27, 2026 | zacks.com

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade

July 27, 2026 | zacks.com

Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects

July 27, 2026 | zacks.com

HC Wainwright Predicts NovoCure's Q2 Earnings (NASDAQ:NVCR)

July 27, 2026 | marketbeat.com

NovoCure's strongest quarter ever isn't enough to stop NVCR stock from sliding

July 25, 2026 | msn.com

NovoCure (NVCR) Lifts 2026 Guidance After Record Quarter While Fair Value Debate Builds

July 25, 2026 | finance.yahoo.com

NovoCure: Why I'm Fading The Q2 Earnings Rally

July 24, 2026 | seekingalpha.com

NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)

July 24, 2026 | seekingalpha.com

NovoCure (NASDAQ:NVCR) Shares Gap Up on Strong Earnings

July 24, 2026 | marketbeat.com

NovoCure (NASDAQ:NVCR) Price Target Raised to $20.00 at Wedbush

July 24, 2026 | marketbeat.com

FY2029 EPS Estimates for NovoCure Decreased by HC Wainwright

July 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BWAY, ESTA, ATRC, and NVCR Company Descriptions

AtriCure NASDAQ:ATRC

$44.30 +0.81 (+1.86%)

Closing price 04:00 PM Eastern

Extended Trading

$44.33 +0.03 (+0.07%)

As of 07:34 PM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Brainsway NASDAQ:BWAY

$16.32 -0.15 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$16.42 +0.10 (+0.61%)

As of 07:34 PM Eastern

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Establishment Labs NASDAQ:ESTA

$79.47 +3.88 (+5.13%)

Closing price 04:00 PM Eastern

Extended Trading

$79.46 0.00 (-0.01%)

As of 07:34 PM Eastern

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

NovoCure NASDAQ:NVCR

$16.95 -0.43 (-2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$17.26 +0.31 (+1.80%)

As of 07:39 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BWAY, ESTA, ATRC, and NVCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BWAY, ESTA, ATRC, and NVCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BWAY, ESTA, ATRC, and NVCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BWAY, ESTA, ATRC, and NVCR Company Descriptions

AtriCure NASDAQ:ATRC

Brainsway NASDAQ:BWAY

Establishment Labs NASDAQ:ESTA

NovoCure NASDAQ:NVCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BWAY, ESTA, ATRC, and NVCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BWAY, ESTA, ATRC, and NVCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BWAY, ESTA, ATRC, and NVCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BWAY, ESTA, ATRC, and NVCR Company Descriptions

AtriCure NASDAQ:ATRC

Brainsway NASDAQ:BWAY

Establishment Labs NASDAQ:ESTA

NovoCure NASDAQ:NVCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools